Immunovant Shifts Focus to Next-Generation FcRn Inhibitor IMVT-1402, Delaying Batoclimab Development ###

###
1. Immunovant Shifts Focus: Immunovant is shifting its focus from batoclimab to IMVT-1402, a next-generation FcRn inhibitor, for the treatment of autoimmune diseases.
2. IMVT-1402 Advantages: IMVT-1402 has shown promising early results, including deep IgG lowering with minimal impact on albumin and LDL levels, and is expected to have composition of matter patent protection through at least 2042.
3. Batoclimab Delay: The development of batoclimab will be delayed, with extended trials in chronic inflammatory demyelinating polyneuropathy (CIDP) and myasthenia gravis, to gather more data that will aid in the development of IMVT-1402.
4. Competitive Landscape: Immunovant is entering a competitive space with approved drugs like Vyvgart from Argenx and a competitor from UCB, as well as other companies like Biohaven and Roche working on similar treatments.
5. Roivant Connection: Immunovant is a portfolio company of Roivant, a 'hub and spoke' biotech that houses drug programs in individual startups, and has seen promising results from its FcRn inhibitor nipocalimab.